GlaxoSmithKline (NYSE:GSK) is set to post its quarterly earnings results on Wednesday, July 24th. Analysts expect GlaxoSmithKline to post earnings of $0.65 per share for the quarter. GlaxoSmithKline has set its FY 2019 guidance at $1.38-1.44 EPS.
GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, May 1st. The pharmaceutical company reported $0.79 EPS for the quarter, beating the Zacks’ consensus estimate of $0.66 by $0.13. The business had revenue of $9.98 billion during the quarter, compared to analysts’ expectations of $9.86 billion. GlaxoSmithKline had a net margin of 12.27% and a return on equity of 157.04%. On average, analysts expect GlaxoSmithKline to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Shares of NYSE GSK opened at $41.13 on Tuesday. The firm has a 50-day simple moving average of $40.39. The firm has a market capitalization of $101.61 billion, a PE ratio of 13.02, a price-to-earnings-growth ratio of 2.15 and a beta of 0.74. The company has a debt-to-equity ratio of 6.92, a current ratio of 0.72 and a quick ratio of 0.48. GlaxoSmithKline has a 52 week low of $36.41 and a 52 week high of $42.20.
In other news, Director Plc Glaxosmithkline acquired 385,714 shares of the business’s stock in a transaction that occurred on Tuesday, May 28th. The stock was purchased at an average cost of $14.00 per share, for a total transaction of $5,399,996.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is currently owned by company insiders.
A number of equities research analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Green Brick Partners from a “sell” rating to a “hold” rating in a research report on Thursday, April 25th. Cowen reiterated a “buy” rating on shares of Aptinyx in a research report on Monday, June 10th. Finally, Morgan Stanley assumed coverage on shares of in a research report on Monday, June 17th. They issued an “equal weight” rating and a GBX 215 ($2.81) target price for the company. One equities research analyst has rated the stock with a sell rating, sixteen have issued a hold rating and three have given a buy rating to the stock. GlaxoSmithKline presently has an average rating of “Hold” and an average target price of $42.28.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.